

**Tchaikapharma High Quality Medicines Inc.**  
**Interim statement of Financial status**  
**as of 30 of September 2020**

	30.09.2020	31.12.2019
	BGN'000	BGN'000
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment	38 640	26 981
Intangible assets	3 172	2 725
Assets with usable assets	263	420
Trade receivables	4 930	4 930
<b>Total non-current assets</b>	<b>47 005</b>	<b>35 056</b>
<b>Current assets</b>		
Inventories	10 615	8 763
Trade and other receivables	59 726	74 020
Current corporate income tax	-	-
Treasury shares redeemed	1	1
Cash and cash equivalents	296	40
<b>Total current assets</b>	<b>70 638</b>	<b>82 824</b>
<b>Total assets</b>	<b>117 643</b>	<b>117 880</b>
<b>LIABILITIES</b>		
<b>Equity</b>		
Share capital	82 200	82 200
Reserves	11 775	11 775
Retained earnings	6 513	2 568
<b>Total</b>	<b>100 488</b>	<b>96 543</b>
<b>Non-current liabilities</b>		
Long-term loans	1 876	2 037
Deferred tax liabilities	1 308	1 308
Retirement benefit obligations	159	159
<b>Total non-current liabilities</b>	<b>3 343</b>	<b>3 504</b>
<b>Current liabilities</b>		
Trade and other liabilities	3 542	7 095
Short-term loans	9 784	9 784
Current portion of long-term loans	449	616
Current corporate income tax		142
Other tax liabilities	37	196
<b>Total current liabilities</b>	<b>13 812</b>	<b>17 833</b>
<b>Total liabilities</b>	<b>17 155</b>	<b>21 337</b>
<b>Total equity and liabilities</b>	<b>117 643</b>	<b>117 880</b>

Date of preparation: 28.10.2020


Sofia

Prepared by:.....

/ P. Moneva /

Executive Director:.....

/B. Georgiev/



**Tchaikapharma High Quality Medicines Inc.**  
**Interim statement of comprehensive income**  
**as of 30 of September 2020**

	<b>30.09.2020</b>	<b>30.09.2019</b>
	<b>BGN'000</b>	<b>BGN'000</b>
Revenue	32 665	28 307
Other income	54	1
<b>Total income</b>	<b>32 719</b>	<b>28 308</b>
Carrying amount of goods sold	(719)	(632)
Changes in inventories of finished products and work in progress	(397)	1 067
Materials and services	(20 437)	(16 394)
Personnel expenses	(3 475)	(3 027)
Depreciation / amortisation expenses	(3 169)	(3 400)
Other expenses	(137)	(575)
Finance income	52	10
Finance costs	(302)	(254)
<b>Total expenses</b>	<b>(28 584)</b>	<b>(23 205)</b>
<b>Profit before taxation</b>	<b>4 135</b>	<b>5 103</b>
Corporate income tax expense	(190)	(184)
<b>Profit/Loss for the period</b>	<b>3 945</b>	<b>4 919</b>
<b>Total comprehensive income for the period</b>		
Earnings per share / in BGN per 1 share /	0.05	0.06

Date of preparation: 28.10.2020

Sofia

Prepared by:.....

/ P. Moneva /

Executive Director:.....

/B. Georgiev/



**Tchaikapharma High Quality Medicines Inc.**  
**Interim cash flow statement**  
**as of 30 of September 2020**

	<b>30.09.2020</b>	<b>30.09.2019</b>
	<i>BGN'000</i>	<i>BGN'000</i>
<b>Cash flows from operating activities</b>		
Proceeds from sale of finished products, goods and services	27 324	23 597
Payments to suppliers of materials, goods and services	(16 982)	(13 462)
Payments to personnel	(3 228)	(2 829)
Payments of interest and dividends	(332)	(309)
Other proceeds / payments	(3 523)	(5 294)
<b>Net cash flows</b>	<b>3 259</b>	<b>1 703</b>
<b>Cash flows from investing activities</b>		
Payments on non-current assets acquired	(2 655)	(770)
<b>Net cash flows</b>	<b>(2 655)</b>	<b>(770)</b>
<b>Cash flows from financial activities</b>		
Proceeds from loans	131	148
Payments on loans	(131)	(147)
Payment of interest, dividends	(147)	(181)
Payments on finance lease	(201)	(968)
Other proceeds/payments from treasury shares		4
<b>Net cash flows</b>	<b>(348)</b>	<b>(1 144)</b>
<b>Change in cash and cash equivalents</b>		
	<b>256</b>	<b>(211)</b>
Cash and cash equivalents at the beginning of the period	40	250
Cash and cash equivalents at the end of the period	296	39

Date of preparation: 28.10.2020

Sofia

Prepared by:.....

/ P. Moneva /

Executive  
Director:.....

/B. Georgiev /



**Tchaikapharma High Quality Medicines Inc.**  
**Interim statement on changes in equity**  
**as of 30 of September 2020**

	Registered (share) capital <i>BGN'000</i>	Revaluation reserves <i>BGN'000</i>	Other reserves <i>BGN'000</i>	Retained earnings / loss <i>BGN'000</i>	Total equity <i>BGN'000</i>
<b>Balance as of 01.01.2019</b>	<b>72 200</b>	<b>4 124</b>	<b>6 477</b>	<b>11 199</b>	<b>94 000</b>
Profit/loss for the period				2 568	2 568
Other comprehensive income		(25)			(25)
Including from tax effect of the revaluation of property, plant and equipment					
<b>Total comprehensive income</b>		<b>(25)</b>		<b>2 568</b>	<b>2 543</b>
Issue of shares by the owners	10 000			(10 000)	
Dividends accrued					
Tantiemmes accrued					
Profit transferred to reserves			1 199	(1 199)	
<b>Total amount of income and expenses recognised during the period</b>	<b>10 000</b>		<b>1 199</b>	<b>(11 199)</b>	
<b>Balance as of 31.12.2019</b>	<b>82 200</b>	<b>4 099</b>	<b>7 676</b>	<b>2 568</b>	<b>96 543</b>
<b>Balance as of 01.01.2020</b>	<b>82 200</b>	<b>4 099</b>	<b>7 676</b>	<b>2 568</b>	<b>96 543</b>
Profit/loss for the period				3 945	3 945
Other comprehensive income					
<b>Total comprehensive income</b>				<b>3 945</b>	<b>3 945</b>
Issue of shares by the owners					
Dividends accrued					
Tantiemmes accrued					
Profit transferred to reserves					
<b>Total amount of income and expenses recognised during the period</b>					
<b>Balance as of 30.09.2020</b>	<b>82 200</b>	<b>4 099</b>	<b>7 676</b>	<b>6 513</b>	<b>100 488</b>

Date of preparation: 28.10.2020  
Sofia

Prepared by: .....  
/P. Moneva/

Executive Director: .....  
/B. Georgiev /

